MyShare
Key factors
| sym | SNBP |
| exch | US |
| MCap | 31.84M |
| Beta | 0.129 |
| EPS | -1.08 |
| Div date | 0000-00-00 |
Yesterday
| sym | SNBP |
| exch | US |
| close | 4.37 |
| 50 Day MA | 3.068 |
| 200 Day MA | 5.070 |
| 52 Week High | 9.99 |
| 52 Week Low | 2.37 |
| Target Price | 9.0 |
| Market Cap Mln | 31.84 |
Share statistics
| Shares Outstanding | 9649.43K |
| Shares Float | 6741.86K |
| Percent Institutions | 8.676 |
| PercentInsiders | 19.02 |
| SharesShort | 23527 |
| Short Ratio | 1.09 |
| Shares Short Prior Month | 24871 |
| Short Percent | 0.289 |
| Short Percent Float | 0.289 |
Income
| Diluted Eps TTM | -0.69 |
earning
| EPS Estimate Current Quarter | -0.12 |
| EPS Estimate Current Year | -0.69 |
| EPS Estimate Next Quarter | -0.11 |
| EPS Estimate Next Year | -0.56 |
| Earnings Share | -1.08 |
Dividend
| Dividend Date | 0000-00-00 |
| Last Split Date | 2017-12-08 |
| Last Split Factor | 1:1 |
business
| Book Value /share | 0.99 |
| Price Book MRQ | 3.567 |
| ReturnOnAssetsTTM | -0.44 |
| ReturnOnEquityTTM | -0.81 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Biotechnology |
| Gic Sector | Health Care |
| Gic Sub Industry | Biotechnology |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | US86664M2061 |
| CIK | 0001029125 |
| Code | SNBP |
| Employer Id Number | 87-0543922 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2020-11-19 |
info
| Fiscal Year End | December |
| Full Time Employees | 4.0 |
| IPODate | 2017 |
| International Domestic | Domestic |
| MostRecent Quarter | 2020-09-30 |
Contact
| Name | Sun BioPharma, Inc |
| Address | 712 Vista Boulevard, Waconia, MN, United States, 55387 |
| Country Name | USA |
| Phone | 952 479 1196 |
| Web URL | www.sunbiopharma.com |
Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.